![From QSR to QMSR: Meeting FDA’s New Requirements From QSR to QMSR: Meeting FDA’s New Requirements](https://www.fdanews.com/ext/resources/Book-Covers-NEW/From-QSR-to-QMSR-500.png?height=200&t=1714569011&width=200)
Home » PURE BIOSCIENCE REPORTS THIRD QUARTER AND NINE-MONTH RESULTS
PURE BIOSCIENCE REPORTS THIRD QUARTER AND NINE-MONTH RESULTS
June 15, 2006
PURE Bioscience today reported financial results for the third quarter and nine-month period ended April 30, 2006. For the third quarter, the Company reported revenues of $44,300
from continuing operations, as compared with revenues of $41,400 in the third
quarter of the prior year. The Company reported a third quarter loss from continuing
operations before taxes of ($871,500), or ($0.04) per share, as compared with
a loss of ($528,800), or ($0.04) per share in the same period last year.
PR
Newswire
KEYWORDS FDAnews Drug Daily Bulletin
Upcoming Events
-
21Oct